Ned Sharp­less' 'brain­child' nabs a speedy FDA re­view for small cell lung can­cer drug

It was an­i­mal da­ta on G1 Ther­a­peu­tics’ on­col­o­gy drug tri­laci­clib that orig­i­nal­ly at­tract­ed cur­rent CEO Mark Vel­le­ca to the com­pa­ny six years ago. And now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.